DAVID FARON: Open Payments
NPI 1306894464 · COLORADO SPRINGS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,622 in 41 payments from 11 companies in 2025. Trend: 2023 $870 · 2024 $659 · 2025 $1,622
Food & beverage: $1,622
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $383 |
| Otsuka America Pharmaceutical, Inc. | 8 | $352 |
| Vanda Pharmaceuticals Inc. | 6 | $253 |
| ABBVIE INC. | 6 | $144 |
| Alkermes, Inc. | 1 | $126 |
| E.R. Squibb & Sons, L.L.C. | 1 | $120 |
| Lundbeck LLC | 5 | $100 |
| Neurocrine BioSciences, Inc. | 2 | $59 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
Products named: REXULTI, CAPLYTA, FANAPT, VRAYLAR, LYBALVI, COBENFY, INGREZZA, HETLIOZ.
Industry payments across CO — which companies pay providers there.
